Tuesday 5 June 2018

Biocon shares hit record high as cancer drug Pegfilgrastim gets USFDA nod

Shares of Biocon hit a record high of Rs 695 per share, up 6% on the BSE in opening deal in otherwise weak market, after the company and its partner Mylan have received nod for their first biosimilar of cancer medicine Pegfilgrastim from the US drug regulator for selling in the American market.

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php
Posted by at
Labels: , , , , , ,

1 comment:

  1. Phani Kumar10 October 2020 at 15:32

    This Information is really good and informative. Thanks for it.
    Check below links and get useful information.
    Bharat Bond ETF

    ReplyDelete

Subscribe to: Post Comments (Atom)